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Certain human papillomaviruses (HPVs) cause most cervical cancer, which remains a significant source of
morbidity and mortality among women worldwide. HPV recombinant virus-like particles (VLPs) are promising
vaccine candidates for controlling anogenital HPV disease and are now being evaluated as a parenteral vaccine
modality in human subjects. Vaccines formulated for injection generally are more costly, more difficult to
administer, and less acceptable to recipients than are mucosally administered vaccines. Since oral delivery
represents an attractive alternative to parenteral injection for large-scale human vaccination, the oral immu-
nogenicity of HPV type 11 (HPV-11) VLPs in mice was previously investigated; it was found that a modest
systemic neutralizing antibody response was induced (R. C. Rose, C. Lane, S. Wilson, J. A. Suzich, E. Rybicki,
and A. L. Williamson, Vaccine 17:2129–2135, 1999). Here we examine whether VLPs of other genotypes may
also be immunogenic when administered orally and whether mucosal adjuvants can be used to enhance VLP
oral immunogenicity. We show that HPV-16 and HPV-18 VLPs are immunogenic when administered orally and
that oral coadministration of these antigens with Escherichia coli heat-labile enterotoxin (LT) mutant R192G
(LT R192G) or CpG DNA can significantly improve anti-VLP humoral responses in peripheral blood and in
genital mucosal secretions. Our results also suggest that LT R192G may be superior to CpG DNA in this
ability. These findings support the concept of oral immunization against anogenital HPV disease and suggest
that clinical studies involving this approach may be warranted.
Papillomaviruses are small DNA viruses that infect verte-
brate hosts, including humans, and cause the formation of
hyperproliferative epithelial lesions (41). More than 80 human
papillomaviruses (HPVs) have been identified and classified
on the basis of genetic sequence differences (12). Approxi-
mately half of HPVs tend to infect cutaneous skin and usually
cause only benign disease (e.g., plantar or common warts),
while others more often infect oral or anogenital mucosal
epithelium (3). Certain mucosal HPVs, including type 16
(HPV-16), HPV-18, HPV-31, HPV-45, and a few others, are
known to cause most cervical cancers (48). Worldwide, cancer
of the cervix is the second leading cause of cancer death in
women (behind breast cancer) and is the most common form
of cancer among women in developing countries (4), with an
estimated 500,000 cases diagnosed each year, resulting in over
200,000 deaths annually (49). Other consequences of mucosal
HPV infection include condyloma acuminatum (i.e., benign
anogenital warts) and recurrent respiratory papillomatosis,
which are caused primarily by HPV-6 and HPV-11 (3). These
and other clinical associations have generated great interest in
the development of vaccines capable of preventing HPV infec-
tion.
HPV is difficult to study because the virus cannot be grown
efficiently in cell culture. The virion consists of a circular dou-
ble-stranded DNA genome of about 8,000 bp contained within
a nonenveloped capsid consisting of major (L1) and minor
(L2) structural proteins. When expressed in a recombinant
system, L1 self-assembles in the absence of L2 into noninfec-
tious virus-like particles (VLPs), which replicate virion mor-
phology and antigenicity (18, 21, 36). Several groups of inves-
tigators have contributed to the development of a rationale for
testing VLPs in human volunteers for immunoprophylactic
efficacy against anogenital HPV disease. It has been shown, for
example, that VLPs of genital HPVs induce antibodies that
efficiently neutralize infectious genital HPV virions (10, 38, 47)
and that genotype-dependent L1 amino acid sequence varia-
tion determines serotype specificity (15, 33–35, 47). Impor-
tantly, immunization with VLPs of animal papillomaviruses
has been shown to confer protection from experimental chal-
lenge in relevant animal models (5, 22, 42). Protection against
challenge has also been achieved by passive transfer of VLP
postimmune serum to naive animals (42), suggesting that im-
munity from infection may be antibody mediated.
Most cases of oncogenic HPV infection are sexually trans-
mitted; therefore, protection from infection may depend to
some extent on immunity acting at genital mucosal surfaces
(28). Mucosal routes of immunization generally are superior to
parenteral routes for the induction of mucosal responses (26).
Adjuvants are usually required, however, to boost mucosal
responses and to prevent the induction of tolerance (26). Chol-
era toxin (CT), Escherichia coli heat-labile enterotoxin (LT),
and their genetically detoxified derivatives are promising mu-
cosal adjuvants for coadministered protein antigens (8). Mu-
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tants of LT have been developed in an effort to dissociate
adjuvanticity from toxicity. One of these, designated LT
R192G, was constructed by site-directed mutagenesis to intro-
duce a single amino acid substitution into the active subunit
(13). This mutation rendered the toxin insensitive to trypsin
activation and thus greatly diminished toxicity without altering
the adjuvanticity of the native molecule. Several recent studies
have evaluated LT R192G and found it to be an effective
FIG. 1. Dose-dependent antibody responses after VLP oral immunization. VLPs of HPV-16 or HPV-18 were administered to nine female
Swiss-Webster mice per group. Sera were collected 12 weeks after primary immunization and evaluated in a VLP ELISA against the same antigens
used for immunization. Data are reported as mean log10 ELISA titers plus standard errors of the means. i.m., intramuscular.
FIG. 2. Serum IgG antibody responses in outbred mice. Nine female Swiss-Webster mice per group were immunized orally as described in
Materials and Methods. Sera were collected 2 weeks after the second booster immunization, and ELISA end-point titers were determined. In the
box plot analysis shown, each box includes the middle 50% of values, and the horizontal bar within represents the median end-point titer. The short
horizontal lines at the ends of the vertical lines extending above and below the boxes are the inner fences (43). The asterisk indicates a P value
of ,0.05.
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mucosal adjuvant (7, 9, 17, 31). Synthetic oligodeoxynucleo-
tides containing unmethylated CpG dinucleotide motifs (CpG
DNA) provide another promising mucosal adjuvant (23, 27).
Accumulating evidence has indicated that CpG DNA has po-
tent immunostimulatory properties (23, 25, 45). While the
mechanism of action is unclear at present, recent evidence has
suggested that CpG DNA acts through a mammalian Toll-like
receptor that may have evolved for the purpose of distinguish-
ing between bacterial and mammalian DNA (19).
The induction of a modest systemic neutralizing response in
mice immunized orally with HPV-11 VLPs without adjuvant
was previously reported (37). Here we investigate whether
coadministration of VLPs with the mucosal adjuvant LT
R192G or CpG DNA can improve VLP oral immunogenicity.
MATERIALS AND METHODS
Animals. Female Swiss-Webster mice were obtained from Taconic Laborato-
ries (Germantown, N.Y.). Female BALB/c mice were obtained from Harlan, Inc.
(Indianapolis, Ind.). Mice were used at ages ranging from 8 to 12 weeks. All
animals were housed and used in accordance with institutional guidelines.
FIG. 3. Kinetics of serum IgG responses after oral administration of VLPs with and without adjuvants. Ten female BALB/c mice per group
were immunized orally with HPV-16 (A) or HPV-18 (B) VLPs either alone (filled circles) or with CpG DNA (open circles) or LT R192G (filled
triangles). Pre- and postimmune sera were collected at the indicated times and evaluated in an ELISA. Arrows denote immunization times. Group
mean end-point titers were calculated from log10-transformed values. Bars indicate standard errors of the means.
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Antigens. Purified baculovirus-expressed HPV-16 and HPV-18 L1 VLPs were
provided by MedImmune, Inc., Gaithersburg, Md., and were produced essen-
tially as described previously (35, 36).
Adjuvants. E. coli LT R192G was produced as previously described (13) and
reconstituted in sterile phosphate-buffered saline (PBS) (1 mg/ml) prior to use.
CpG DNA (CpG ODN 1826; 59-TCCATGACGTTCCTGACGTT-39) (46) was
synthesized with a nuclease-resistant phosphorothioate backbone (Synthetic Ge-
netics, San Diego, Calif.) and resuspended in sterile PBS (1 mg/ml) prior to use.
Immunizations. To compare the relative immunogenicities of VLPs adminis-
tered parenterally versus orally, mice were immunized with 0.3 mg of HPV-16 or
HPV-18 VLPs by intramuscular injection or with 1, 3, or 9 mg of VLPs by oral
gavage as previously described (37). In other experiments, animals were immu-
nized orally with VLP antigens at a single dose level (10 mg), with or without LT
R192G (10 mg) or CpG DNA (10 mg).
ELISA. Pre- and postimmune sera were obtained by retrobulbar collection;
vaginal washes were collected with a pipette (0.1 ml of sterile PBS). VLP anti-
body levels were measured with an enzyme-linked immunosorbent assay
(ELISA) as previously described (37). Briefly, Nunc MaxiSorp (Nalgene, Rosk-
ilde, Denmark) 96-well microtiter plates were coated with 0.1 mg of antigen in
PBS per well, incubated at 4°C overnight, blocked with 2% bovine serum albumin
(BSA) (diluent-blocking solution; Kirkegaard & Perry [K&P] Laboratories,
Gaithersburg, Md.), and washed four times with 0.05% Tween 20 in PBS. Test
sera were diluted 1:50 in BSA diluent-blocking solution, serially diluted twofold
down the microtiter plate, and incubated for 90 min at room temperature to
permit antibody binding. Control mouse sera with known HPV-16 or HPV-18
VLP antibody titers were added to each plate. Plates were washed as before and
reacted for 90 min at room temperature with alkaline phosphatase-conjugated
goat anti-mouse immunoglobulin G (IgG) (Southern Biotechnology Associates,
Inc., Birmingham, Ala.) diluted 1:5,000 in BSA diluent-blocking solution. IgA
antibody levels were determined with goat anti-mouse IgA (Southern Biotech-
nology Associates, Inc.) as the secondary antibody as previously described (16,
37). The reaction was developed with 100 ml of substrate (p-nitrophenyl phos-
phate; Sigma Chemical Co., Inc., St. Louis, Mo.) per well for 1 h. Absorbance
measurements were obtained at 405 nm using an automated plate reader. End-
point titers were calculated as the reciprocal of the highest serum dilution with
an absorbance value greater than twice the background absorbance value of each
serum sample tested. Nonresponder serum samples were assigned a value of
one-half the lowest serum dilution tested.
Serum IgG subclass ELISA. Mouse IgG subclass standards and corresponding
alkaline phosphatase-conjugated antibodies were obtained from Southern Bio-
technology Associates. The specificity, sensitivity, and optimal dilution of each
reagent were confirmed prior to use. Serial twofold dilutions of test sera were
prepared with diluent-blocking solution, added to VLP-coated wells, and incu-
bated for 90 min at room temperature. After four washes, IgG subclass-specific
conjugated antibodies were added to plates and incubated for 90 min at room
temperature. End-point titers were determined as described above.
Vaginal wash ELISA. Pre- and postimmune vaginal wash specimens were
diluted 1:16 in PBS, added to VLP-coated wells, serially diluted down the mi-
crotiter plate, and reacted for 90 min at room temperature. After four washes,
100 ml of alkaline phosphatase-conjugated goat anti-mouse IgG or alkaline
phosphatase-conjugated goat anti-mouse IgA (Southern Biotechnology Associ-
ates) diluted 1:5,000 in diluent-blocking solution was added to each well in
alternate rows of the plate. Conjugated antibodies were incubated for 90 min at
room temperature, and levels of VLP-specific vaginal IgG and IgA antibodies
were determined by measuring the absorbance at 405 nm. Additional evaluations
of the same specimens indicated that concentrations of total IgA were essentially
equivalent among groups, with only minor variations (P 5 0.80) (data not
shown).
Evaluation of VLP polyclonal antibody specificities. VLP postimmune sera
were tested with an ELISA against either native or denatured VLPs of either
HPV-16 or HPV-18 as previously described (37). Postimmune sera were also
tested with a VLP binding inhibition assay against previously characterized
virus-neutralizing polyclonal antibodies as previously described (15).
Preparation of lymphoid cell suspensions. Single-cell suspensions were ob-
tained from the spleen by gently pressing the organ between two sterile frosted
end slides; dissociated cells were then washed into a 60-mm plate containing 5%
fetal bovine serum-buffered salt solution (Sigma). Mesenteric and inguinal lymph
nodes and Peyer’s patches were isolated by careful excision and processed as
described above. Cell viability was determined by trypan blue exclusion, and cells
were diluted to a density of 2 3 106/ml in complete medium.
Lymphoproliferation assay. Single-cell suspensions were prepared as de-
scribed above and plated (2 3 105 cells/well) in a 96-well flat-bottom plate
(Costar, Corning, N.Y.) with or without antigen. Test (i.e., stimulated) wells
contained the same antigen as that used for immunization at one of three dose
levels (i.e., 0.03, 0.3, or 3.0 mg per well); control (unstimulated) wells did not
contain antigen. Cultures were maintained in a final volume of 200 ml at 37°C in
5% CO2 for 96 h. The plate was pulsed with l mCi of 3H-thymidine (Amersham
Pharmacia Biotech, Piscataway, N.J.) for the final 20 h of incubation. Cultures
were harvested using a Packard (Meriden, Conn.) harvester, and incorporated
radioactivity was quantitated with a Packard Matrix 96 direct beta counter.
Results from triplicate wells were averaged and used to calculate a stimulation
index: mean counts per minute of stimulated cells divided by mean counts per
minute of unstimulated cells.
Statistical analysis. A nonparametric (Kruskal-Wallis) rank sum test was used
for one-way analysis of variance, followed by a multiple-comparison procedure
(Dunn’s test) to compare antibody titers between groups. Nonresponders were
included in all calculations. Statistical significance was assessed at a P value of
,0.05 for all comparisons.
RESULTS
VLP systemic antibody responses. It was previously found
that a 100-mg oral dose of HPV-11 VLPs was adequate to
induce a serum neutralizing response (37). To characterize
further the oral dose response to VLPs, purified VLPs (1, 3, or
9 mg of VLP antigen) of HPV-16 or HPV-18 in 0.1 ml of PBS
were administered orally to groups of female Swiss-Webster
mice (nine per group). For comparison, other mice received
0.3 mg of the same immunogens by intramuscular injection
(nine per group). Boosting was done 2 and 6 weeks after
TABLE 1. Serum antibody titers in BALB/c mice 16
weeks postimmunizationa
Antibody Immunogen Adjuvant
Titer
Median Interquartilerange
IgG HPV-16 VLPs None 1,200 800–6,400
CpG DNA 12,800 6,400–51,200
LT R192G 102,400 44,800–102,400
HPV-18 VLPs None 1,600 800–5,600
CpG DNA 38,400 12,800–51,200
LT R192G 51,200 25,600–102,400
IgA HPV-16 VLPs None 100 100–200
CpG DNA 1,200 800–3,200
LT R192G 3,200 3,200–3,200
HPV-18 VLPs None 400 400–700
CpG DNA 3,200 3,200–3,200
LT R192G 3,200 3,200–3,200
a The P value was ,0.05 for all comparisons with control groups.
TABLE 2. Serum antibody isotype analysis
Immunogen
(ELISA antigen) Adjuvant
Geometric mean
titera:
IgG1 IgG2a
HPV-16 VLPs None 459 746
CpG DNA 7,352 19,401
LT R192G 51,200 47,771
HPV-18 VLPs None 429 1,493
CpG DNA 7,352 47,771
LT R192G 29,407 95,543
a Ten mice per group.
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primary immunizations. Consistent with previous results (37),
HPV-16 and HPV-18 VLPs were immunogenic when admin-
istered orally without adjuvant and induced dose-dependent
antibody responses, with ELISA end-point titers of 1022 to
1023 (Fig. 1). However, parenteral injection of a smaller
amount (i.e., 0.3 mg) of the same immunogens elicited titers
(.104) relatively higher than those induced by oral immuniza-
tion. Consistent with other reported results (24), in this study
parenteral administration of VLPs without adjuvant was much
(.100-fold) more efficient than oral immunization for the in-
duction of anti-VLP humoral responses.
To evaluate whether adjuvant use could enhance VLP oral
immunogenicity, we next immunized mice (female Swiss-Web-
ster; nine per group) orally with HPV-16 VLPs at a single dose
(10 mg), alone or in combination with LT R192G (10 mg) or
CpG DNA (10 mg). Boosting was done at 2 and 6 weeks after
primary immunizations. Sera were collected 2 weeks after the
second boost and evaluated with an ELISA for anti-VLP an-
tibodies. Mice immunized orally with VLPs in combination
with LT R192G had serum IgG titers that were significantly
higher (median, 204,800; interquartile range, 78,400 to
512,000) than the titers induced by VLPs alone (median, 1,600;
interquartile range, 88 to 3,200) (P , 0.05). Titers obtained in
mice immunized with VLPs in combination with CpG DNA
(median, 25,600; interquartile range, 400 to 64,000) were not
significantly different from those of either the control or the LT
R192G adjuvant group (Fig. 2).
Next, BALB/c mice were used to evaluate the kinetics of
anti-VLP serum antibody responses after oral immunization.
In this experiment, animals received a single booster inocula-
tion 2 weeks after primary immunizations. The results (Fig. 3)
indicated that oral administration of VLPs in combination with
either adjuvant significantly increased serum IgG titers over
those obtained with VLPs alone (the P value was ,0.05 for
each group receiving antigen plus adjuvant in comparison with
the control [no adjuvant] group at each time point after pri-
mary immunizations). Four months after primary immuniza-
tions, VLP serum IgG and IgA ELISA titers in all antigen-
adjuvant groups were significantly higher than titers in
corresponding control groups (Table 1).
Serum IgG subclass analysis. Sera from mice that were
positive for VLP-specific IgG were evaluated for the presence
of anti-VLP IgG1 and IgG2a antibodies (Table 2). The use of
LT R192G was associated with the induction of IgG1 and
IgG2a, whereas in animals immunized with CpG DNA, a more
Th1-like (IgG2a) pattern emerged (Table 2).
FIG. 4. Conformational dependence and type specificity of orally induced VLP serum IgG. BALB/c mice were immunized as described in
Materials and Methods, and a subset of three mice from each group was tested in a VLP ELISA against native HPV-16 VLPs (black bars),
denatured HPV-16 VLPs (white bars), native HPV-18 VLPs (gray bars), or denatured HPV-18 VLPs (hatched bars). OD, optical density.
TABLE 3. Mucosal antibody analysis
Immunogen
(ELISA antigen) Antibody Adjuvant
Titer
P , 0.05a
Median Interquartilerange
HPV-16 VLPs IgA None 12 12–12
CpG DNA 36 12–192 No
LT R192G 288 48–384 Yes
IgG None 12 12–12
CpG DNA 18 12–48 No
LT R192G 24 12–48 Yes
HPV-18 VLPs IgA None 12 12–21
CpG DNA 192 48–192 Yes
LT R192G 576 384–768 Yes
IgG None 12 12–12
CpG DNA 24 24–48 No
LT R192G 48 24–48 Yes
a For comparisons with control groups.
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VLP mucosal antibody responses. To determine whether
oral immunization could induce anti-VLP humoral responses
in genital mucosal secretions, vaginal wash specimens collected
from the same mice were tested with an ELISA (Table 3).
BALB/c mice immunized orally with HPV-16 VLPs in combi-
nation with LT R192G demonstrated significantly higher titers
of anti-VLP IgG and IgA antibodies than were obtained with
VLPs administered either alone or in combination with CpG
DNA (Table 3). Similar results were obtained with HPV-18
VLPs; however, in this instance, the use of either adjuvant
significantly enhanced IgA responses over responses in control
animals (Table 3). Differences between groups that received
VLPs in combination with LT R192G versus CpG DNA were
not significant. A similar evaluation of specimens collected
from parenterally immunized animals (from the experiment
depicted in Fig. 1) revealed the presence of anti-VLP IgG but
not IgA antibodies in genital mucosal secretions (data not
shown).
Evaluation of VLP polyclonal antibody specificities. VLP-
induced virus-neutralizing polyclonal antibody specificities
characteristically exhibit the properties of conformational de-
pendence and virus genotype specificity (40). To examine
whether coadministered adjuvants may alter VLP polyclonal
antibody specificities, we evaluated VLP postimmune poly-
clonal sera for conformational dependence, HPV genotype
specificity, and susceptibility to VLP binding inhibition by pre-
viously characterized neutralizing polyclonal antibodies essen-
tially as previously described (15). A subset of the sera tested
above (Fig. 3) was further examined with an ELISA against
native and denatured VLPs of HPV-16 or HPV-18. The results
indicated that the coadministration of VLPs with either CpG
DNA or LT R192G had little effect on the conformational
dependence or genotype specificity of the responses (Fig. 4).
Moreover, in a VLP binding inhibition assay (15), there were
no discernible differences in the ability of a previously charac-
terized HPV-16 virion-neutralizing polyclonal antiserum (47)
to inhibit HPV-16 VLP binding by postimmune sera from
animals immunized with VLPs alone or in combination with
CpG DNA or LT R192G (Fig. 5). Thus, properties character-
istically associated with virus-neutralizing antibody specificities
appeared to be unaltered by these adjuvants.
Lymphoproliferative responses. Peyer’s patches, spleens,
and inguinal lymph nodes were recovered from mice at 1 and
10 weeks after boosting with VLPs with or without adjuvants.
Immune cells were dissociated, restimulated in vitro with in-
creasing amounts of the same antigen as that used for immu-
nization, and then evaluated for proliferation by 3H-thymidine
incorporation. Mice that received VLPs in combination with
LT R192G demonstrated strong proliferative responses in gut-
associated lymphoid tissues (GALT) (i.e., mesenteric lymph
nodes, Peyer’s patches, and spleens) (Fig. 6 and data not
shown). Lymphocytes recovered from non-GALT organs (i.e.,
inguinal lymph nodes) did not respond to antigen restimula-
tion (data not shown). Only minimal proliferative responses
were detected in lymphocytes recovered from animals immu-
nized with VLPs alone (data not shown) or in combination
with CpG DNA (Fig. 6). These results confirmed VLP oral
delivery to GALT and provided additional evidence that, in
these experiments, the adjuvant effect of LT R192G was rela-
tively greater than that of CpG DNA.
FIG. 5. VLP binding inhibition assay. BALB/c mice were immunized as described in Materials and Methods. Two serum samples from each
immunization group were tested in a VLP binding inhibition ELISA (see Materials and Methods for details) using as a blocking antibody a
previously described rabbit polyclonal antiserum (R-079) that efficiently neutralizes HPV-16 virions (47). Mice were immunized orally with either
HPV-16 VLPs alone (circles), HPV-16 VLPs in combination with CpG DNA (squares), or HPV-16 VLPs in combination with LT R192G
(triangles).
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DISCUSSION
HPV VLP oral immunogenicity in mice was assessed with
and without mucosal adjuvants. Consistent with previous re-
sults (37), VLPs of oncogenic anogenital HPV-16 and HPV-18
were immunogenic when administered orally and induced
type-specific IgG and IgA antibody responses in serum and in
genital mucosal secretions. Adjuvant use significantly en-
hanced these responses, and the overall effect of LT R192G on
humoral and cellular responses was found to be greater than
that of CpG DNA. VLP-adjuvant administration elicited high
(104 to 105) and durable (.4 months) humoral responses that
were 2 to 3 orders of magnitude higher than responses gener-
ated without adjuvant. Strong HPV-16 and HPV-18 anti-VLP
responses in BALB/c mice were achieved after two immuniza-
tions, whereas a third immunization was required to generate
comparable responses in outbred (i.e., Swiss-Webster) mice.
LT R192G significantly enhanced anti-VLP IgA responses in
mucosal secretions and, to a lesser extent, CpG DNA also
enhanced these responses. Antibody isotype analysis revealed
that LT R192G was able to enhance the production of both
IgG1 and IgG2a antibodies in serum, whereas CpG DNA
primarily elicited a more Th1-like (IgG2a) response. Consis-
tent with a somewhat greater ability to enhance humoral re-
sponses, the use of the LT R192G mutant was also associated
with antigen dose-dependent proliferative responses in mesen-
teric lymphoid tissues. This result also served to confirm that
orally administered VLPs were being delivered to intestinal
mucosal immune inductive sites.
Titers elicited by VLPs in combination with either adjuvant
were found to exceed titers induced by parenteral vaccination
with the same immunogens. The parenterally induced titers
depicted in Fig. 1 were elicited with a relatively smaller amount
of antigen (0.3 mg); nevertheless, these observations support
the potential feasibility of oral immunization against anogeni-
tal HPV disease. Although virion neutralization assays were
not performed in the present study, the work of several groups
has consistently indicated a correlation between VLP ELISA
titers and virion-pseudovirion neutralization titers in vitro (2,
33, 37, 39, 44, 47) and in vivo (6, 11, 38). Consequently, the
VLP ELISA is now regarded as a good surrogate assay for the
detection of virus-neutralizing activity (40). The overall results
indicate that VLPs are efficient oral immunogens when coad-
ministered with a potent mucosal adjuvant and suggest further-
more that VLP oral immunization can induce potentially pro-
tective immune responses at a level that may prove to be
efficacious for controlling anogenital HPV disease.
We previously (37) reported the initial induction of a Th1-
like (IgG2a) response in BALB/c mice after oral immunization
with HPV-11 VLPs without adjuvant but found that IgG1
antibody titers soon became comparable in magnitude (i.e.,
within 8 weeks following primary immunizations). Here we
obtained a similar antibody profile following coadministration
of VLPs with LT R192G. In contrast, and consistent with
results reported elsewhere (25), coadministration of VLPs with
CpG DNA induced a more Th1-like (IgG2a) response. In the
context of anogenital HPV disease, potential advantages or
disadvantages of such adjuvant properties are not currently
known.
Preclinical studies of VLPs using alternate immunization
routes have been limited (2, 14, 24, 29, 30, 37), and an optimal
method for mucosal administration has not yet been defined.
Other groups investigating alternate immunization strategies
have reported results similar to the present results. Induction
of anti-VLP serum IgG and vaginal IgA antibody responses
FIG. 6. Mesenteric lymphoproliferative responses after oral administration of VLPs with adjuvant. Mice were immunized and boosted with
HPV-16 VLPs in combination with CpG DNA (squares) or LT (R192G) (triangles) as described in Materials and Methods. At 1 week (open
symbols) or 10 weeks (filled symbols) after boosting, three mice from each group were sacrificed; gut mesenteric lymphocytes were isolated in vitro
and then restimulated with the same antigens as those used for immunization in the amounts indicated. Mesenteric lymphocytes recovered from
mice immunized with VLPs alone were not responsive to restimulation (data not shown).
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has been demonstrated, for example, following intranasal im-
munization of mice with HPV-16 VLPs coformulated with CT
(2, 14). Balmelli et al. (2) found that VLPs were immunogenic
when administered intranasally but were poorly immunogenic
when administered orally with or without CT (2). Similarly,
Dupuy et al. (14) reported anti-HPV-16 VLP serum IgG titers
of greater than 104 and vaginal IgA titers of greater than 102
after intranasal administration of VLPs with CT, whereas
VLPs administered intranasally without CT were only poorly
immunogenic (14). Taken together, the present and previous
results (37) indicate that VLPs are good oral immunogens
when coadministered with the adjuvants used in the present
study (i.e., LT R192G or CpG DNA). Differences in adjuvants
used, immunization methods, dosage levels, or sources of an-
tigens or adjuvants may account for the observed discrepancies.
Observed differences in the magnitudes of the immune re-
sponses elicited after immunizations with HPV-16 versus
HPV-18 capsids suggest the possibility of inherent immuno-
genic differences between these genotypes (e.g., compare Fig.
3A and B). While it may be interesting to consider how such
differences might affect the relative prevalence of one genotype
versus another, similar evaluations of alternate lots of immu-
nogens will be required to rule out the possibility that the
observed differences instead merely reflect slight variations in
preparative methods.
Vaccines represent the most efficient and cost-effective
means of preventing disease; however, the full potential of
vaccination to improve public health is not yet realized (20).
Oral vaccines offer practical and financial advantages over par-
enterally administered vaccines. From a practical standpoint,
mucosal vaccines are easier to administer and less invasive
than parenteral vaccines and thus are more likely to facilitate
mass vaccination programs in underdeveloped regions. The
development of needle-free vaccines has a high priority, in part
due to the recognition that blood-borne diseases are often
transmitted through the reuse of needles (1, 32). The relative
simplicity of oral immunization could very well facilitate vac-
cine distribution in developing regions, which bear the brunt of
genital HPV disease (4).
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